148 related articles for article (PubMed ID: 8591079)
1. Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy.
Lise M; Nitti D; Marchet A; Sahmoud T; Duez N; Fornasiero A; dos Santos JG; Labianca R; Lasser P; Gignoux M
Ann Surg Oncol; 1995 Nov; 2(6):495-501. PubMed ID: 8591079
[TBL] [Abstract][Full Text] [Related]
2. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.
Lise M; Nitti D; Marchet A; Sahmoud T; Buyse M; Duez N; Fiorentino M; Dos Santos JG; Labianca R; Rougier P
J Clin Oncol; 1995 Nov; 13(11):2757-63. PubMed ID: 7595735
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study.
Macdonald JS; Fleming TR; Peterson RF; Berenberg JL; McClure S; Chapman RA; Eyre HJ; Solanki D; Cruz AB; Gagliano R
Ann Surg Oncol; 1995 Nov; 2(6):488-94. PubMed ID: 8591078
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
[TBL] [Abstract][Full Text] [Related]
5. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
Chang HM; Jung KH; Kim TY; Kim WS; Yang HK; Lee KU; Choe KJ; Heo DS; Bang YJ; Kim NK
Ann Oncol; 2002 Nov; 13(11):1779-85. PubMed ID: 12419751
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant FAM2 in resectable gastric cancer.
Lise M; Nitti D; Buyse M; Marchet A; Fiorentino M; Dos Santos JG; Duez N
Anticancer Res; 1989; 9(4):1017-21. PubMed ID: 2683987
[TBL] [Abstract][Full Text] [Related]
7. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
[TBL] [Abstract][Full Text] [Related]
8. Phase-III clinical trial of adjuvant FAM2 (5-FU, adriamycin and mitomycin C) vs control in resectable gastric cancer: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group.
Lise M; Nitti D; Buyse M; Cartei G; Fornasiero A; Guimaraes dos Santos J; Duez N
Recent Results Cancer Res; 1988; 110():36-43. PubMed ID: 3043595
[No Abstract] [Full Text] [Related]
9. 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion.
Choi JH; Kim YB; Lim HY; Park JS; Kim HC; Cho YK; Han SW; Kim MW; Joo HJ
Hepatogastroenterology; 2007; 54(73):290-7. PubMed ID: 17419278
[TBL] [Abstract][Full Text] [Related]
10. No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer.
Chen S; Chen YB; Zhou ZW; Li W; Sun XW; Xu DZ; Li YF; Guan YX; Feng XY; Zhan YQ
Am J Clin Oncol; 2011 Jun; 34(3):309-13. PubMed ID: 20838324
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
Jeung HC; Moon YW; Rha SY; Yoo NC; Roh JK; Noh SH; Min JS; Kim BS; Chung HC
Ann Oncol; 2008 Mar; 19(3):520-6. PubMed ID: 18029971
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
Ryoo BY; Kang YK; Im YH; Kim YJ; Kim BS; Kim TY; Jung SH; Park JH; Baek HJ; Kim YC; Shim YM; Kim CM; Zo JI
Am J Clin Oncol; 1999 Jun; 22(3):253-7. PubMed ID: 10362331
[TBL] [Abstract][Full Text] [Related]
13. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
Díez M; Medrano MJ; Gutierrez A; López A; Mugüerza JM; Hernández P; Lozano O; Noguerales F; Ruíz A; Granell J
Anticancer Res; 2000; 20(5C):3929-33. PubMed ID: 11268479
[TBL] [Abstract][Full Text] [Related]
14. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer.
Popiela T; Kulig J; Czupryna A; Szczepanik AM; Zembala M
Gastric Cancer; 2004; 7(4):240-5. PubMed ID: 15616772
[TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.
Park JO; Chung HC; Cho JY; Rha SY; You NC; Kim JH; Noh SH; Kim CB; Min JS; Kim BS; Roh JK
Am J Clin Oncol; 1997 Oct; 20(5):484-9. PubMed ID: 9345333
[TBL] [Abstract][Full Text] [Related]
16. Long term (five-year) survival following radical surgical treatment plus adjuvant chemotherapy (FAM) in advanced gastric cancer: a controlled study.
Bresciani C; Gama-Rodrigues J; Strassmann V; Waitzberg DL; Matsuda M; Pinotti HW
Rev Hosp Clin Fac Med Sao Paulo; 2000; 55(4):129-36. PubMed ID: 11082221
[TBL] [Abstract][Full Text] [Related]
17. Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Choi JH; Lim HY; Joo HJ; Kim HS; Yi JW; Kim HC; Cho YK; Kim MW; Lee KB
Br J Cancer; 2002 May; 86(10):1578-85. PubMed ID: 12085207
[TBL] [Abstract][Full Text] [Related]
18. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
Kim SY; Park HC; Yoon C; Yoon HJ; Choi YM; Cho KS
Cancer; 1998 Nov; 83(10):2054-9. PubMed ID: 9827708
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group.
Nakajima T; Nashimoto A; Kitamura M; Kito T; Iwanaga T; Okabayashi K; Goto M
Lancet; 1999 Jul; 354(9175):273-7. PubMed ID: 10440302
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study.
Neri B; de Leonardis V; Romano S; Andreoli F; Pernice LM; Bruno L; Borrelli D; Valeri A; Fabbroni S; Intini C; Cini G
Br J Cancer; 1996 Feb; 73(4):549-52. PubMed ID: 8595173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
